Interviews

Keeping up with fast-paced clinical, regulatory, and policy innovation in healthcare is difficult. Our video interviews provide insight from key experts in the field of biosimilars, and help keep you informed.
Sal Patel, JD, partner at Schiff Hardin, LLP, explains why he expects to see more settlements between drug manufacturers in the future.
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses which therapeutic areas need biosimilars the most. 
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, addresses key differences between the US market and the EU market for biosimilars.
Sal Patel, JD, partner at Schiff Hardin, LLP, explains why he is watching litigations concerning rheumatoid arthritis drugs closely.
Imron Aly, JD, partner at Schiff Hardin, LLP, explains how lessons learned from Hatch-Waxman proceedings can be applied to Biologics Price Competition and Innovation Act (BPCIA) litigation.
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses the challenges that biosimilar developers face in getting their products to market. 
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses lessons learned from the launch of the company’s biosimilar filgrastim. 
Louis Tharp, cofounder and executive director of the Global Healthy Living Foundation, discusses what drives high drug costs in the United States.
Louis Tharp, cofounder and executive director of the Global Healthy Living Foundation, discusses the burden of high-cost biologics for patients with rheumatic diseases.
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses successes in drug patent challenges. 
Click here to view Biosimilars CME Activities


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2018 Intellisphere, LLC. All Rights Reserved.